About this trial
Enhanced Recovery After Surgery (ERAS) protocols have been of increasing interest in the surgical community for decades. The emphasis has been development of protocols to maximize pain control post-operatively without the use of opioids. While this approach has been studied extensively in the oncology surgery literature, little data exists on the utility of ERAS protocols in the setting of breast conserving surgery (BCS), which is a type of surgery to remove breast cancer while saving as much of the breast as possible. The purpose of this study is to determine the utility of implementing ERAS protocols in breast cancer patients undergoing breast conserving surgery. Study participants will be randomized to either ERAS protocol or standard peri-operative care without ERAS. The study will assess the how many opioid prescriptions are given in the first week after surgery and how much pain participants report right after surgery. Investigators will also look at how long participants stay in the recovery room and if medicine for nausea is needed.
Eligibility criteria
Qualifiers
Males or females 19 years of age or older
Able to provide study-specific informed consent
Histologic confirmation of breast cancer on core needle biopsy
Clinical or radiographic cT1-T3 N0 disease
Disqualifiers
Pregnant
Contraindications to ERAS protocol components
Undergoing lumpectomy without sentinel lymph node biopsy, mastectomy, or other specified procedures
Diagnosed with cT4 or N1-3 disease
Trial design
Treatments tested in this trial
- ERAS Protocol
- Standard Perioperative Care